文献速递流行病学与生物统计真实世界研究与卫生经济

鱼类来源ω-3脂肪酸膳食摄入与糖尿病视网膜病变风险

Dietary Intake of Omega-3 Fatty Acids From Fish and Risk of Diabetic Retinopathy.
PubMed 文献 · JAMA · 2017-01-01

该研究在PREDIMED随机临床试验框架内开展前瞻性分析,纳入3482例55至80岁2型糖尿病患者,评估基线膳食长链ω-3多不饱和脂肪酸(LCω3PUFA)摄入是否与威胁视力的糖尿病视网膜病变(DR)发生率降低相关。中位随访6年共记录69例新发事件,达到LCω3PUFA推荐量(≥500 mg/d)者较未达标者威胁视力DR风险相对降低48%(HR 0.52,95%CI 0.31–0.88;P=.001)。作者认为每周2份油性鱼即可达到该摄入量,并与威胁视力DR风险降低相关。

要点

  • 在2型糖尿病中老年人中,基线LCω3PUFA摄入≥500 mg/d者威胁视力DR风险低于<500 mg/d者(HR 0.52,95%CI 0.31–0.88;P=.001)。
  • 每年更新的LCω3PUFA摄入分析显示关联略强(相对危险度0.48,95%CI 0.28–0.82;P=.007)。
  • 作者认为每周2份油性鱼即可达到≥500 mg/d的LCω3PUFA摄入。

核心结论

  • 在2型糖尿病中老年人群中,膳食LCω3PUFA摄入至少500 mg/d与威胁视力DR风险降低相关,作者认为该摄入量通过每周2份油性鱼即可实现。

研究设计与样本

  • 在PREDIMED随机临床试验框架内于2015年末设计的前瞻性研究,试验在西班牙初级卫生保健中心开展。
  • 2003至2009年招募3614例既往诊断2型糖尿病、年龄55至80岁个体,3482例有完整数据(48%为男性,平均年龄67岁)。
  • 暴露为通过经验证的食物频率问卷评估的膳食LCω3PUFA摄入是否达到至少500 mg/d(用于心血管一级预防的推荐量)。
  • 主要结局为需激光光凝、玻璃体切除术和/或抗血管生成治疗的DR,由外部裁定委员会确认。

主要发现

  • 3482例参与者中2611例(75%)达到LCω3PUFA推荐量。
  • 中位随访6年期间记录69例新发事件。
  • 调整年龄、性别、干预组及生活方式和临床变量后,基线达到LCω3PUFA推荐量(≥500 mg/d)者较未达标者(<500 mg/d)威胁视力DR风险相对降低48%(HR 0.52,95%CI 0.31–0.88;P=.001)。
  • 每年更新LCω3PUFA摄入的分析中关联略强(相对危险度0.48,95%CI 0.28–0.82;P=.007)。

关键数值与推荐

  • 膳食LCω3PUFA推荐量为至少500 mg/d(用于心血管一级预防),由经验证的食物频率问卷评估。
  • 主要结局为需激光光凝、玻璃体切除术和/或抗血管生成治疗的DR,由外部裁定委员会确认。

临床怎么用

  • 作者认为至少500 mg/d的膳食LCω3PUFA摄入与威胁视力DR风险降低相关,该摄入量通过每周2份油性鱼即可实现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Diabetic retinopathy (DR) is a devastating complication of individuals with type 2 diabetes mellitus. The retina is rich in long-chain ω−3 polyunsaturated fatty acids (LCω3PUFAs), which are substrate for oxylipins with anti-inflammatory and antiangiogenic properties. Experimental models support dietary LCω3PUFA protection against DR, but clinical data are lacking. OBJECTIVE: To determine whether LCω3PUFA intake relates to a decreased incidence of sight-threatening DR in individuals with type 2 diabetes older than 55 years. DESIGN, SETTING, AND PARTICIPANTS: In late 2015, we conceived a prospective study within the randomized clinical trial Prevención con Dieta Mediterránea (PREDIMED), testing Mediterranean diets supplemented with extra virgin olive oil or nuts vs a control diet for primary cardiovascular prevention. The trial was conducted in primary health care centers in Spain. From 2003 to 2009, 3614 individuals aged 55 to 80 years with a previous diagnosis of type 2 diabetes were recruited. Full data were available for 3482 participants (48% men; mean age 67 years). EXPOSURES: Meeting the dietary LCω3PUFA recommendation of at least 500 mg/d for primary cardiovascular prevention, as assessed by a validated food-frequency questionnaire. MAIN OUTCOMES AND MEASURES: The main outcome was incident DR requiring laser photocoagulation, vitrectomy, and/or antiangiogenic therapy confirmed by an external adjudication committee. RESULTS: Of the 3482 participants, 48% were men and the mean age was 67 years. A total of 2611 participants (75%) met target LCω3PUFA recommendation. During a median follow-up of 6 years, we documented 69 new events. After adjusting for age, sex, intervention group, and lifestyle and clinical variables, participants meeting the LCω3PUFA recommendation at baseline (≥500 mg/d) compared with those not fulfilling this recommendation (<500 mg/d) showed a 48% relatively reduced risk of incident sight-threatening DR, with a hazard ratio of 0.52 (95% CI, 0.31–0.88; P = .001). This association was slightly stronger for yearly updated LCω3PUFA intake (relative risk, 0.48; 95% CI, 0.28–0.82; P = .007). CONCLUSIONS AND RELEVANCE: In middle-aged and older individuals with type 2 diabetes, intake of at least 500 mg/d of dietary LCω3PUFA, easily achievable with 2 weekly servings of oily fish, is associated with a decreased risk of sight-threatening DR. Our results concur with findings from experimental models and the current model of DR pathogenesis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: ISRCTN35739639

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chew EY. Dietary Intake of Omega-3 Fatty Acids From Fish and Risk of Diabetic Retinopathy. JAMA. 2017. PMID: 28586878. doi:10.1001/jama.2017.1926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。